Stonegate Updates Coverage on Burcon Nutrascience Corporation (TSX: BU) 4Q26
Burcon has moved from commissioning and into early utilization, with growing customer volume setting up better fixed-cost absorption at Galesburg. The Company completed commissioning and launched commercial production across Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein in FY26. Revenue increased sequentially to $0.83M in 4Q26 from $0.74M in 3Q26, and management […]
Stonegate Capital Partners Updates Coverage on Seabridge Gold Inc. (NYSE: SA) 1Q26
Seabridge Gold is moving through a catalyst-dense phase as KSM partnership discussions advance alongside FS preparation, BC permitting support, the Valor Gold spin-out, and the maiden Snip North resource. Quarterly financials remain secondary, though SA ended 1Q26 with C$126.9M of cash and raised C$35.8M through its ATM program. In our view, SA is increasingly converting […]
Stonegate Capital Partners Updates Coverage on Incannex Healthcare Inc. (NasdaqGM: IXHL) 3Q26
IXHL’s 3Q26 results and subsequent clinical update move IHL-42X from Phase 2 validation toward dose-optimization execution ahead of Phase 3. The key change is the start of DReAMzz, a crossover study designed to refine the dronabinol/acetazolamide ratio, incorporate FDA feedback, and strengthen the Phase 3 protocol before larger late-stage capital is committed. For investors, the […]
Stonegate Capital Partners Updates Coverage on Hooker Furniture Corporation (NASDAQ: HOFT) 1Q27
HOFT reported revenue, operating income, and adj EPS of $69.5M, $1.6M, and $0.10, respectively. This compares to our/consensus estimates of $71.8M/$66.3M, ($0.6)M/($0.9)M, and ($0.04)/($0.07). HOFT reported 1Q27 revenue was down 2.4% y/y, as softer Hooker Branded and Domestic Upholstery sales were partially offset by higher hospitality shipments. The key read-through is that last year’s portfolio […]
Stonegate Capital Partners Initiates Coverage on Creative Media & Trust Corp. (NASDAQ: CMCT)
CMCT’s 1Q26 update shifts the story from balance sheet repair to FFO conversion. Reported results remained noisy given the late-quarter preferred redemption, but the Company has now redeemed $396.2M of preferred stock since September 2024, sold First Western, retired its recourse credit facility, and moved closer to its long-term target capital structure. The March redemption […]
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) 1Q26
Cingulate’s latest update shifts the near-term CTx-1301 setup from a PDUFAdriven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed. The FDA issued a Complete Response Letter for the CTx-1301 NDA focused on specific CMC information requests, with no current clinical safety or efficacy concerns […]
Stonegate Capital Partners Initiates Coverage on SES AI Corp. (NYSE: SES)
SES’ 1Q26 update further shifts the story from EV battery development toward a commercialization model led by ESS, with drone cells, materials, and Molecular Universe adding clearer 2H26/2027 revenue paths. Revenue beat expectations, though Q1 benefited from ~$1.5M of 4Q25 revenue shifting into the period, so the better read is not run-rate extrapolation but improved […]
Stonegate Capital Partners Initiates Coverage on Postal Realty Trust Inc. (NYSE: PSTL)
PSTL’s 1Q26 update improved the setup by increasing forward revenue visibility and accelerating acquisition capacity at the same time. In our view, the thesis is becoming easier to underwrite, as the lease platform is producing clearer internal growth through mark-to-market resets and escalators, while improved capital access is adding a more active external growth leg. […]
Stonegate Capital Partners Updates Coverage on Seabridge Gold Inc. (NYSE: SA) 1Q26
AB Science’s latest update narrows the story around two priorities: masitinib in ALS and AB8939 in AML. The key change is not FY25 revenue, but clearer capital allocation, a more defined ALS Phase 3 setup, and a firm CTFI offer that adds potential risk-sharing around AB23005. MS and AD remain meaningful upside, but are now […]
Stonegate Capital Partners Updates Coverage on Seabridge Gold Inc. (NYSE: SA) 1Q26
Seabridge Gold is moving through a catalyst-dense phase as KSM partnership discussions advance alongside FS preparation, BC permitting support, the Valor Gold spin-out, and the maiden Snip North resource. Quarterly financials remain secondary, though SA ended 1Q26 with C$126.9M of cash and raised C$35.8M through its ATM program. In our view, SA is increasingly converting […]